CF PharmTech (02652.HK) disclosed that on 20 February 2026, it repurchased 8,000 shares on the Hong Kong Stock Exchange at an average price of HKD 36.28 per share. The highest repurchase price was HKD 36.50, the lowest was HKD 36.08, and the total consideration amounted to HKD 290,260.00. The repurchased shares were placed in treasury, bringing the total treasury shares to 0.36 million.

Following the transaction, the number of issued shares excluding treasury shares decreased to 301.86 million, while the total issued share count remained at 302.22 million. The repurchase falls under a mandate dated 16 December 2025, which authorizes up to 30.22 million shares. The company is subject to a moratorium until 22 March 2026 regarding the issuance of new shares or the sale of any treasury shares.